BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, July 26, 2026
Breaking News: Single-cell transcriptome study points to new drug targets for preeclampsiaBreaking News: Single-cell transcriptome study points to new drug targets for preeclampsiaBreaking News: Science fiction realized: BCI tech is here
Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
BioWorld Science, Cardiovascular RSS Feed RSS

Cardiovascular

siRNA-mediated knockdown of AP-1 improves PAH in hamsters

Feb. 21, 2024
A team at the Institute of Cellular Biology and Pathology ‘Nicolae Simionescu’ of Romanian Academy aimed to assess the effects of targeted siRNA for AP-1 silencing on restoring structural...
Read More
Cardiovascular

C3 inhibitor CP40-KK protects rats from PAH development

Feb. 20, 2024
Pulmonary arterial hypertension (PAH) is a severe condition characterized by vasoconstriction and remodeling of the small pulmonary arteries, driven by a complement-dependent activation of macrophages, for which an effective treatment is lacking. Chinese researchers have investigated the potential of a complement C3 inhibitor polypeptide, CP40-KK, as an approach for treating PAH. To do this, they used a model in which PAH was induced in rats by monocrotaline.
Read More
Cardiovascular

Nextgen Bioscience presents new autotaxin inhibitors

Feb. 15, 2024
Nextgen Bioscience Co. Ltd. has divulged ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors reported to be useful for the treatment of cancer, fibrosis, cardiovascular, inflammatory, respiratory, metabolic, eye and renal disorders, among others.<
Read More
Neurology/Psychiatric

New mouse model of COVID-19-induced cerebrovascular embolic complications

Feb. 15, 2024
Researchers from Mercer University have presented a middle cerebral artery/ferric chloride (MCA/FeCl3) thromboembolic mouse model of COVID-19-induced stroke and cerebrovascular complications.
Read More
Biomarkers

TLNRD1 identified as new regulator of CCM signaling

Feb. 13, 2024
Researchers from Broad Institute Inc. and affiliated organizations have reported data from a study that highlighted a new variant-to-gene-to-program (V2G2P) approach designed to link variants from genome-wide association studies (GWAS) to genes and identify their convergence onto specific disease-associated transcriptional programs.
Read More
Digital cardiology illustration
Cardiovascular

Windtree renews partnership with Chang Gung University to advance SERCA2a research for cardiovascular disease

Feb. 2, 2024
Windtree Therapeutics Inc. has renewed its partnership with Chang Gung University to further research on SERCA2a, an important target for the company’s cardiovascular portfolio.
Read More
Heart and lungs
Cardiovascular

MCJ protein at the heart of new options to manage pulmonary hypertension

Feb. 1, 2024
By Coia Dulsat
Researchers at the Spanish National Center for Cardiovascular Research (CNIC) have identified a new target that may open new avenues into pulmonary hypertension (PH) treatment. Their findings were published in Science Advances on Jan. 19, 2024.
Read More
Neurology/Psychiatric

Kv2.1 inhibitor with promising anticerebral ischemia activity in rats

Jan. 31, 2024
Researchers from Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College have discovered novel selective Kv2.1 inhibitors as potential therapeutic candidates for the treatment of ischemic stroke.
Read More
Cardiovascular

P4HA1 overexpression promotes post-ischemic tissue repair

Jan. 23, 2024
Collagen prolyl 4-hydroxylase (P4H) is an α-ketoglutarate (α-KG)-dependent dioxygenase, and prolyl 4-hydroxylase subunit α1 (P4HA1) is the major isoform among the catalytic subunits of P4H. It has been previously demonstrated that P4HA1 promotes angiogenesis in tumors, and bioinformatics analysis has identified P4HA1 as a glycolysis-related gene in various cancers.
Read More
G protein-coupled receptors: rhodopsin and the T-cell, dopamine and GABA B receptors
Cardiovascular

New G protein-coupled receptor kinase 5 inhibitor disclosed

Jan. 19, 2024
G protein-coupled receptor kinase 5 (GRK5) promotes cardiac hypertrophy; it is involved in...
Read More
Previous 1 2 … 30 31 32 33 34 35 36 37 38 … 852 853 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 24, 2026.
  • Red CAR T cell on blue blackground

    To viral or not to viral: In vivo CAR T debates delivery tech

    BioWorld Asia
    The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
  • Cell nucleus architecture

    4D Nucleome opens new wave of gene regulation research, discovery

    BioWorld
    After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
  • International currency symbols

    Capital remains selective in ‘barbell’ biotech market

    BioWorld Asia
    Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
  • Other news to note for July 22, 2026

    BioWorld
    Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing